Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dosage and Administration: Oral administration on an empty stomach, once daily. Applicable to 50mg (2 capsules of 25mg), 100mg (1 capsule of 100mg), 200mg (2 capsules of 100mg), 300mg (3 capsules of 100mg), 400mg (4 capsules of 100mg), and 500mg (5 capsules of 100mg) dose groups. Duration of Treatment: Multiple dosing, with each treatment cycle consisting of 28 days.”In the company’s words, NCT07514065 on ClinicalTrials.gov
- Main trialPhase 1
- “TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment. Preclinical studies confirm its selective targeting of CDK4/6 and DYRK2, a eukaryotic CMGC family kinase. In palbociclib-resistant cell lines, TSL2109 downregulates cell cycle-related proteins and DYRK2 pathway ribosomal synthesis regulators (RRS1, CDK2), and upregulates p53, thus exerting synergistic antitumor effects and overcoming resistance to enzalutamide and palbociclib. As a small-molecule inhibitor with novel targets, structure and mechanism,…”In the company’s words, NCT07514065 on ClinicalTrials.gov
- Other names
- DYRK2-CDK4/6
Other drugs for Metastatic Castration-Resistant Prostate Cancer Patients
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2026 | TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026